To The Moon

$Novo-Nordisk A/S(NVO)$

In a move that surprised many investors, Novo Nordisk announced that its CEO—who has led the company since 2017—will be stepping down. Importantly, the transition will not be immediate: he’s agreed to remain in his role until a successor is identified and brought up to speed. While the headlines may suggest instability, this type of managed leadership change is far preferable to a sudden departure.

This news comes hot on the heels of UnitedHealth’s CEO also stepping down, adding to a growing narrative of executive turnover in the healthcare sector. Some investors are starting to wonder: is healthcare becoming a tougher industry to lead?

That’s a broader question, but in this article, I want to focus specifically on Novo Nordisk. With shares down nearly 59% since June 2024, this is no small dip. And when a stock drops that much, two things happen: panic from existing shareholders, and curiosity from value-oriented investors wondering if this is an opportunity.

I’ll walk you through:

• What the CEO change means (and doesn't mean)

• My proprietary discounted cash flow (DCF) valuation

• A look at Novo’s forward P/E ratio and ROIC

• How I interpret the current risks and catalysts

• And finally, my verdict: Is Novo Nordisk a Buy?

What Does the CEO Departure Mean for Investors?

First, let’s put the CEO transition into perspective.

Any time the top executive of a multi-billion-dollar company announces their departure, it raises legitimate concerns. Is there internal turmoil? Did the board push them out? Are there strategic disagreements behind closed doors?

These are fair questions—but in this case, the outgoing CEO is staying on until a replacement is found. That suggests this is an orderly, planned transition, not a forced exit. For shareholders, that makes a big difference. Sudden changes at the top can lead to strategic drift, operational disruption, or culture shock. But when there’s a timeline and continuity plan in place, those risks are significantly reduced.

Also consider this: Novo Nordisk has grown into a global leader in the fast-growing GLP-1 market during this CEO’s tenure. Under his leadership, the company launched and scaled its now-famous weight-loss drug Wegovy, and expanded its pipeline in diabetes, obesity, and cardiovascular health. So while leadership change always introduces a degree of uncertainty, this particular transition appears well-managed.

That said, it’s happening at a tense moment for the company.

GLP-1 Arms Race: From Leader to Laggard?

The GLP-1 category—short for glucagon-like peptide-1 receptor agonists—has become the hottest corner of the pharmaceutical market in recent years. Originally developed to treat diabetes, GLP-1 drugs like Ozempic and Wegovy are now being prescribed for obesity, heart disease, and potentially even Alzheimer’s and addiction in the future.

Novo Nordisk was an early leader, but its crown is slipping. Eli Lilly’s competing product Zepbound has recently overtaken Wegovy in market share across key geographies. That shift has rattled investors.

In fact, Novo’s stock has declined a staggering 59% since June 2024, as concerns mount about its ability to compete with Lilly’s scale, pricing power, and pipeline. The CEO stepping down—no matter how gracefully—only adds to the uncertainty.

But here’s the thing: stock prices often overreact, especially in the short term.

The more important question is whether the company’s fundamentals and valuation still support a long-term investment thesis.

Valuation Deep Dive: Discounted Cash Flow Model

Let’s talk valuation.

Using my updated proprietary DCF model, I estimate Novo Nordisk’s intrinsic value at $150 per share. With the stock currently trading around $63, that suggests it is significantly undervalued.

Key DCF Assumptions:

• Revenue growth: Moderate single-digit CAGR, in line with historical performance and adjusted for GLP-1 competition

• Operating margin: Stable, reflecting Novo’s strong pricing and cost discipline

• Terminal growth rate: 2.5%

• WACC: Between 8–12%, depending on risk profile and macro sensitivity

One of the reasons Novo Nordisk enjoys a lower cost of capital is its non-cyclical business model. Healthcare is not a discretionary expense. When people need treatment—whether for diabetes, obesity, or cardiovascular disease—they don’t wait for a bull market.

This “needs-based” dynamic makes healthcare stocks more resilient during recessions, geopolitical shocks, or even inflationary periods. That resilience contributes to a lower beta and a lower discount rate, which boosts valuation.

In fact, Novo’s beta sits at just 0.67, meaning the stock is 33% less volatile than the broader S&P 500.

Forward P/E: Cheapest in Nearly a Decade

Let’s cross-check the DCF results with a more traditional metric: Forward Price-to-Earnings (P/E).

As of this writing, Novo Nordisk is trading at a forward P/E of 16. That’s the lowest level since 2017. During the pandemic-era boom and GLP-1 hype cycle, the stock often traded at a forward P/E in the 30–35 range.

So not only does the DCF point to undervaluation, but the relative valuation also supports that conclusion. You’re essentially paying pre-GLP-1 prices for a company that still holds a valuable IP portfolio, global distribution, and a strong R&D pipeline.

OIC vs. WACC: Measuring Capital Efficiency

One of my favorite long-term performance indicators is Return on Invested Capital (ROIC). It measures how well a company converts investor money into profitable projects.

Novo Nordisk currently has an ROIC of 26.88%.

Compare that to its WACC, which is approximately 8.5%, and you’re looking at a return-to-cost ratio of over 3:1. That’s a remarkable spread, and it tells us that the company continues to deploy capital efficiently, even amid competitive pressure.

Companies that can consistently earn returns far above their cost of capital tend to outperform the market over long periods.

Macro Volatility Makes Healthcare More Attractive

It’s worth taking a step back and looking at the broader macro environment.

• Consumer confidence is deteriorating

• Stock market volatility has increased

• President Trump’s newly announced Liberation Day tariffs have added geopolitical risk to the equation

• Recession probabilities are rising

In this kind of environment, defensive sectors like healthcare tend to outperform. They are less correlated with economic cycles, less reliant on consumer discretionary spending, and more protected by long-term demographic tailwinds.

As the global population ages, and as obesity rates continue to climb, demand for Novo Nordisk’s portfolio of treatments is likely to remain stable—if not grow.

Risks to Consider

No investment is without risk, and Novo Nordisk is no exception.

1. Leadership uncertainty – Even with a smooth handoff, strategic vision could shift under new management.

2. Competitive pressure – Eli Lilly is investing heavily in R&D, pricing, and supply chain optimization to dominate the GLP-1 space.

3. Regulatory scrutiny – Pricing and marketing practices for obesity drugs could face pushback in both the U.S. and Europe.

4. Currency risk – As a European company earning revenue globally, Novo is exposed to FX volatility.

Still, I believe these risks are well understood and likely priced into the current valuation.

Conclusion: Is Novo Nordisk Stock a Buy After the CEO Steps Down?

In my view, yes with risk.

Despite the CEO’s departure and short-term competitive headwinds, Novo Nordisk remains:

• Financially robust

• Operationally efficient

• Valuation-wise, deeply discounted

At $63, with a fair value estimate of $150, a forward P/E of 16, and a 26.88% ROIC, this stock is attractively priced for long-term investors. While the GLP-1 market is becoming more competitive, the long-term trends in chronic disease, global healthcare access, and demographic shifts remain firmly in Novo’s favor.

Unless the incoming CEO radically changes course—or new data significantly undercuts Wegovy’s efficacy—this dip may prove to be a rare opportunity to buy a global healthcare leader at a generational discount.

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub